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A STUDY ON METABOLIC SYNDROME IN PERSONS SUFFERING FROM 
SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS 
ABSTRACT 
BACKGROUND: 
Schizophrenia is a debilitating chronic illness, and is one of the most 
devastating psychiatric illnesses. Early and appropriate intervention with 
antipsychotics is an important treatment strategy for the patients with first-episode 
schizophrenia. Metabolic syndrome forms one of the most important therapeutic 
objectives in the treatment of schizophrenia. Psychiatrists treating people with 
schizophrenia, hence to balance the therapeutic benefit of antipsychotic medication 
with the risk of metabolic syndrome in present day treatment. 
AIM:  
To study the frequency and risk factors for the onset of metabolic syndrome in 
persons suffering from schizophrenia treated with antipsychotics. 
METHOD AND MATERIALS:  
It is a prospective study done for a period of twelve months (July2017-July 
2018).The 100 samples were chosen from psychiatry outpatient department of 
Institute of Mental Health who were diagnosed as schizophrenia according to ICD 10 
criteria. Divided them into two groups based on the antipsychotics they were started 
on. Group 1 patients were started on Haloperidol and group 2 patients were started on 
risperidone and olanzapine. Socio demographic details and risk factors as per semi 
structured proforma were collected from groups 1 and 2. Blood samples collected 
from the group 1 and 2 at baseline, 1, 3, 6, 12 months of treatment with 
antipsychotics. Waist circumference blood pressure and BMI were measured for the 
group1 and group 2 at baseline, 1, 3, 6, 12 months of treatment with antipsychotics.     
RESULTS:  
In our study, the prevalence of metabolic syndrome in patients suffering from 
schizophrenia treated with antipsychotics at 12 months was 28%. The prevalence was 
high for the treatment with olanzapine (48%) when compared to haloperidol (18%) 
and risperidone (20%). Strong association was present between risk factors (age group 
of 36-40 years of age, positive family history and obesity) and development of 
metabolic syndrome in schizophrenia patients treated with antipsychotics.  
CONCLUSION: 
Prevalence of metabolic syndrome is higher among the patients with 
schizophrenia treated with antipsychotics. Prevalence is higher among the patients 
treated with the second generation antipsychotics. The prevalence of metabolic 
syndrome was associated with the increased risk of contracting cardiovascular 
diseases. It was associated with higher mortality, hence early diagnosis and 
intervention is mandatory in all schizophrenia patients treated with antipsychotics. 
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